Nelson memo

The Nelson Memo: Igniting a Global Open Data Revolution

The landscape of scientific research is undergoing a seismic shift, driven by an urgent demand for transparency, reproducibility, and equitable access. At the epicenter of this transformation in the United States is the Nelson Memo, a policy directive rapidly accelerating the future of open science. With the National Institutes of Health (NIH)'s recent announcement (NOT-OD-25-101)…...
Read More

Top Stories

MAPS 2025

MAPS 2025 Decoded: The Medical Affairs Playbook

At the MAPS Americas 2025 conference in New Orleans, one of...
DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for

Digital and AI were hot topics underpinning many of the...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
Leverage Social Media to Transform Medical Affairs | Promoting Disease Awareness, Ensuring Compliance and Assessing Outcomes

Leveraging Social Media to Transform Medical Affairs

This whitepaper explores the role of social media in enhancing Medical Affairs functions. As digital...
Artificial Intelligence and Writing

Breaking Barriers: Exploring the Power of AI and NLP in Scientific Communication

Learn how medical publication professionals and medical affairs teams can embrace AI and NLP tools...

A Guide to Creating a Robust Patient Engagement Strategy

Get started on effective patient engagement in your pharmaceutical or biotech company with our comprehensive...
people-forming-a-chain

Why Is It Important to Include Patients as Peer Reviewers

Patient peer reviews offer an amazing opportunity to see how HCPs and pharmaceutical companies are...

From Transactional to Transformational: Bringing Patient Centricity to the Next Level

The pharma industry’s focus is shifting from the transactional approach to a transformational approach by...
Stakeholder perspectives on digital scientific content

Digital Scientific Content: Stakeholder Perspectives

What do the different relevant stakeholder groups truly expect from pharma-generated scientific content?...

Learn more ABOUT our company.